Company
Headquarters: Greenfield, IN, United States
Founded: 1954
Employees: 9,000
CEO: Mr. Jeffrey N. Simmons
$7.17 Billion
USD as of Jan. 1, 2024
Company | Market Cap (USD) |
---|---|
Zoetis Inc. | $89.09 B |
MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
Takeda Pharmaceutical Company Limited | $47.71 B |
Haleon plc | $38.90 B |
PPD, Inc. | $16.58 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Elanco Animal Health Incorporated has the following listings and related stock indices.
Stock: NYSE: ELAN wb_incandescent
Stock: FSX: 5EA wb_incandescent
Pharmaceutical drugs (animal)
R. David Hoover (Chairman) Jeff Simmons (CEO)
Revenue: US$3.273 Billion (Fiscal Year Ended December 31, 2020)
Operating income: –US$0.672 Billion (Fiscal Year Ended December 31, 2020)
Net income: –US$0.560 Billion (Fiscal Year Ended December 31, 2020)
Total assets: US$17.692 Billion (Fiscal Year Ended December 31, 2020)
Total equity: US$8.475 Billion (Fiscal Year Ended December 31, 2020)